The level of vitamin D-binding protein (DBP) is increased in the cerebrospinal fluid of patients with Alzheimer's disease (AD), suggesting a relationship with its pathogenesis. In this study, we investigated whether and how DBP is related to AD using several different approaches. A pull-down assay and a surface plasmon resonance binding assay indicated direct interactions between purified DBP and amyloid beta (Ab), which was confirmed in the brain of AD patients and transgenic AD model mice by immunoprecipitation assay and immunohistochemical double-staining method. Moreover, atomic force microscopic examination revealed that DBP reduced Ab aggregation in vitro. DBP also prevented Ab-mediated death in cultured mouse hippocampal HT22 cell line. Finally, DBP decreased Ab-induced synaptic loss in the hippocampus and rescued memory deficits in mice after injection of Ab into the lateral ventricle. These results provide converging evidence that DBP attenuates the harmful effects of Ab by a direct interaction, and suggest that DBP is a promising therapeutic agent for the treatment of AD.
Alzheimer's disease (AD) is one of the most common agerelated neurological disorders. Although the causative factors underlying its pathogenesis have still not been fully elucidated, it is widely thought that amyloid beta (Ab) peptide plays a pivotal role.
1 AD-related brain damage is primarily caused by Ab, the levels of which are strongly correlated with the extent of neurodegeneration and severity of memory deficits. 2, 3 Ab is normally present in soluble form in the plasma and cerebrospinal fluid (CSF) and aggregates and accumulates as amyloid plaques in the brain of AD patients, which has been suggested to be a critical event in the pathogenesis of AD. 2 Currently, many strategies are available for the treatment of AD, and anti-Ab therapy, which includes immunization against Ab and treatment with amyloid-binding agents, is expected to be the most effective approach. 4 CSF and plasma have been reported to contain several circulating Ab-binding proteins, such as transthyretin (TTR), apolipoprotein E (apoE), cystatin C, and albumin, which have been shown to influence Ab-mediated pathology, [5] [6] [7] [8] and have attracted much interest. Several studies have demonstrated that Absequestering proteins may reduce the pathogenesis of AD by binding to Ab, preventing its aggregation, and subsequently inhibiting Ab-induced cytotoxicity. These findings suggest that Ab-binding proteins could play a key role in the pathogenesis of AD and might constitute possible therapeutic agents for its treatment.
Vitamin D-binding protein (DBP), with a molecular weight of approximately 58 kDa, belongs to the albumin gene family and is primarily synthesized in the liver. 9 It is a secretory protein that has been detected in the plasma and CSF at markedly higher concentrations than its ligands. 10, 11 The nomenclature of DBP has changed several times in the past six decades because of the different biological actions that it controls, and has been known as group-specific component globulin, DBP, and DBP-macrophage-activating factor. 12 DBP contains binding sites for several proteins and molecules, including vitamin D, C5a, actin, fatty acids, and endotoxin, suggesting that it is a multifunctional protein. The primary function of DBP is to act as a transport protein for vitamin D and its metabolites. In addition, it exerts several other important physiological functions, including fatty acid transport, macrophage modulation, osteoclast activation, and chemotaxis. 13 One of the most important roles of DBP is to scavenge extracellular toxic actin, which is released into the extracellular space after cell death: DBP interacts with and sequesters monomeric actin and inhibits its polymerization. 13 Similarly, gelsolin, another Ab-binding protein, also interacts with and eliminates actin. A growing body of evidence suggests that DBP has excellent therapeutic potential for vitamin D-deficient conditions, cancer, liver disease, trauma, and osteopetrosis. It is currently undergoing clinical trials in these diseases, which aim to inhibit the growth of various types of cancer, protect against vitamin D intoxication, and correct skeletal defects in osteopetrosis by upregulating the oxidative metabolism in mutant cells and increasing the number of osteoclasts.
Many studies have reported that changes in DBP concentration are linked to the pathology of several diseases, including hepatic failure, diabetes, and multiple sclerosis. 10, [12] [13] [14] Recently, Gressner et al. 11 reported that intrathecal synthesis of DBP is increased in patients with severe neurodegeneration, including AD, and suggested that upregulated DBP may act as an actin scavenger in neurodegenerative diseases. Several other studies also have shown that the level of DBP in CSF is increased in AD patients and suggested that this plays a role in the pathology of AD. 15, 16 However, the functions of extracellular DBP in AD have not yet been elucidated.
These findings prompted us to hypothesize that DBP could play an important role in the pathogenesis of AD. In this study, we investigated whether DBP interacted directly with Ab and inhibited its fibrilization, resulting in the suppression of Ab 1-42 -induced AD pathogenesis in vitro and in vivo. We found that DBP interacted directly with both the Ab 1-42 monomer and oligomer, resulting in a reduced aggregation of Ab. DBP bound to and sequestrated Ab , and prevented neuronal death induced by Ab 1-42 monomer and oligomer in vitro, suggesting that it is an inhibitor of Ab 1-42 neurotoxicity. Moreover, we used mice administered Ab oligomers (AbO) intraventricularly as a model to investigate the preventive potential role of DBP on AbO-triggered cognitive and neuropathological outcomes. We found that DBP improved AbO-associated impairment of cognitive function by inhibiting synaptic degeneration. Our results indicate that DBP has a preventive role in AD pathogenesis by directly binding to Ab.
Results
DBP directly interacts with Ab. We investigated whether Ab binds to DBP using pull-down assay and immunoprecipitation assay (IP) (Figure 1 ). We incubated biotinylated Ab (1, 5 , and 10 mg) with various concentrations of DBP (1, 5, and 10 mg) in test tubes. The specific interaction of DBP with Ab was demonstrated by the pull-down assay, followed by immunoblot analysis with anti-DBP antibody. Lanes 6, 7, and 8 in the top panel of Figure 1a show the binding of DBP (5 mg) to different concentrations of Ab (1, 5 , and 10 mg), and indicating that this is dependent on the concentration of Ab. The pulled-down amounts of DBP and biotin-Ab are shown in the input panels of Figure 1a . We further tested whether DBP and Ab have physiological interaction in vivo using AD animal model, 5 familial AD mutations (5XFAD) mice, which overexpresses Ab in the brain. 56 The cortex of 6-month-old 5XFAD mice was used for IP of DBP and Ab. The specific binding of DBP with Ab in brains of 5XFAD mice was showen by the IP, followed by immunoblot analysis with antiAb-specific antibody, 6E10 (Figure 1b) . No Ab bands were detected in the littermate mice because these mice do not express human APP as well as Ab, which is recognized by 6E10 antibody. These data indicated the direct interaction between DBP and Ab in vitro and in vivo.
DBP binds to both monomeric and oligomeric forms of Ab . Using surface plasmon resonance (SPR) experiments, we examined the direct binding between DBP and various concentrations of monomeric and oligomeric Ab . This SPR method has been used for the highly sensitive real-time measurement of interactions between Ab 1-42 in the flow phase and DBP immobilized on the sensor chip. To study the concentration-dependent binding of Ab to DBP, SPR experiments were conducted with various concentrations of monomeric and oligomeric Ab 1-42 (62.5, 125, 250, 500, and 1000 nM). The measurements indicated that the association of Ab with DBP is dependent on the concentration of Ab (Figure 2 ). These data demonstrated that DBP binds directly to both monomeric and oligomeric Ab with a K D of 1.265 and 108.5 nM, respectively, indicating that DBP has a higher affinity for the monomeric than for the oligomeric form of Ab .
DBP is accumulated in the amyloid plaques in vivo. As many Ab-binding proteins, such as TTR, apoE, apoJ, and apoA1, are known to accumulate with Ab in amyloid No Ab bands were detected in the littermate mice; n ¼ 4 each cases deposits 5, 17 and the level of DBP in CSF is increased in AD patients, 11, 15, 16 we examined whether DBP is present in the amyloid plaques of brains from AD patients and transgenic animal model of AD. We double-stained human AD and control brain with antibodies against Ab (4G8) and DBP. The immunoreactivity of DBP colocalizes with 4G8-stained plaques in the superior temporal cortex of AD patients' brains but not in the control brains (Figure 3a) . Using the same antibodies, we also stained the brains of 6-month-old 5XFAD mice and observed that DBP coincides with Ab in the frontal cortex of 5XFAD mice (Figure 3b ). Consistent with a previous report using same DBP antibody (H300: sc-32899; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 18 DBPexpressing cells were detected in the hypothalamus of 6-month-old 5XFAD mice, demonstrating the specificity of DBP immunoreactivity (Supplementary Figure 1) . Ab accumulation was not detectable in the hypothalamus of 6-month-old 5XFAD mice. These data showed that DBP is present in amyloid deposits of AD brains, implying that endogenously produced DBP can interact with endogenous Ab in vivo.
DBP inhibits the aggregation and oligomerization of Ab . Several Ab-binding proteins have been reported to be negative regulators of Ab polymerization. 8, [19] [20] [21] Using thioflavin T (ThT) fluorescence assay, we assessed whether Ab-binding DBP could affect the Ab aggregation. DBP (1, 10, and 100 mg/ml) treatment showed the dose-dependent inhibition of aggregation of monomeric Ab 1-42 (10 mM), as demonstrated by reduced ThT fluorescence intensity ( Figure 4a ). To further study the inhibitory effects of DBP on Ab 1-42 polymerization, we examined the Ab 1-42 oligomerization by quantifying the oligomer size using atomic force microscopy (AFM). Analysis of AFM images showed that the initial monomeric Ab 1-42 (10 mM) spontaneously polymerized into larger globular aggregates over 24 h. The size and morphology of oligomeric Ab 1-42 particles were similar to those reported previously. 22 When DBP (100 mg/ml) was incubated with monomeric Ab 1-42 , its formation was significantly attenuated (Figure 4b ). Quantitative data revealed that the average perimeter of particles in the samples supplemented with DBP was markedly reduced compared with that of control samples incubated without DBP (Figure 4c ). These results suggest that DBP interacts with and/or sequestrates Ab monomers and oligomers, resulting in a reduction in Ab 1-42 aggregation and oligomerization.
DBP attenuates Ab-induced neuronal cell death in vitro. Neuronal loss and atrophy are one of the hallmarks of and cause of memory deficits in AD in humans. 23, 24 Recent studies showed that Ab-binding heat-shock proteins, which prevent Ab aggregation and oligomerization, inhibit Ab-induced neuronal death. 19, 25 To elucidate the effect of DBP on the cytotoxicity of Ab, we examined whether DBP influences Ab-mediated neuronal death using the MTT assay, MTS assay, and DAPI staining. DBP prevents AbO-induced memory impairment in vivo. To study the effect of DBP on Ab toxicity in vivo, we examined the effect of DBP on Ab-induced cognitive dysfunction in mice. AbO, a major cause of memory impairment in AD, 26 was used to disrupt memory function in mice. Previous reports have shown that Ab-binding proteins or agents reduce the impairment of cognitive function in models of AD.
5, 27 We therefore tested whether injection of DBP into the brain inhibits AbO-induced cognitive impairment. To analyze cognitive function and cognitive task, the Y-maze test was performed. In the Y-maze test, spontaneous alternation was recorded to evaluate spatial and short-term memory, and showed that AbO-injected mice had a lower percentage of spontaneous alternation than sham-operated controls (Figure 6a) . Moreover, the AbO-induced reduction in levels of spontaneous alternation was significantly inhibited by intracerebroventricular injection of 20 mg DBP (Figure 6a ). We observed no significant difference in the total number of arm entries during the Y-maze test in any of the groups, suggesting similar levels of motor function and exploratory activity (Figure 6b) together, the cognitive test shows that central injection of DBP, which binds to AbO, attenuates AbO-induced impairment of cognitive function.
DBP prevents AbO-mediated synaptic degeneration in the hippocampus. In AD, memory deficits are strongly correlated with levels of expression of synaptic proteins 28, 29 and hippocampal synaptic density. 30 Recent studies have shown that AbO binds to dendritic spines and induces synaptic degeneration. 31 We therefore hypothesized that DBP directly interacts with AbO, blocks its subsequent binding to synaptic target structures in the hippocampus, and prevents its synaptotoxicity. We therefore determined whether DBP inhibits AbO-mediated synaptic loss. After immunostaining with antibody to synaptophysin ( Figure 7 ) and postsynaptic density protein 95 (PSD-95) (Supplementary Figure 3) , optical density was measured to compare synaptic density. Quantification of immunoreactivity for synaptophysin and PSD-95 demonstrated that its expression was significantly decreased in both the CA1 stratum radiatum and the CA3 stratum lucidum of the hippocampus in AbO-injected mice compared with the sham-operated group (Figure 7 and Supplementary  Figure 3) . Centrally administered DBP markedly attenuated the AbO-mediated reduction in synaptic density in the CA1 and CA3 subfields of the hippocampus ( Figure 7 and Supplementary Figure 3) . These data indicate that Ab-binding DBP acts as an inhibitor of the synaptic toxicity induced by AbO.
Discussion
Although the level of DBP in CSF has been known to be increased in AD patients, and several lines of evidence have suggested that DBP plays a role in AD, 11, 15, 16, 32 there is no direct evidence of whether or how DBP affects AD-related pathology. Our data clearly show that DBP interacts directly with Ab and reduces the formation of aggregated Ab. Moreover, it protects HT22 cells from Ab-induced death in vitro. Interestingly, central injection of DBP improves the cognitive dysfunction induced by AbO and protects against the reduction in hippocampal synaptic density in mice injected intracerebroventricularly with AbO. These results suggest that DBP has a functional role in binding to and/or sequestering Ab and has multiple therapeutic effects on AD by inhibiting the formation of toxic AbO and protecting against the neurodegeneration and memory impairment induced by Ab toxicity.
DBP is known to have a variety of physiological functions, including the transport of vitamin D, fatty acid transport, immune modulation, osteoclast activation, and chemotaxis, In this study, we observed that DBP from human plasma and CSF interacted with Ab, suggesting that DBP possibly acts as an Ab-transporter protein in the circulation. To our knowledge, this is the first study to demonstrate that DBP plays a role in Ab transport or Ab binding. We propose that the major function of DBP is to bind to and sequester Ab and form DBP-Ab complexes under physiological conditions. The binding sites for several proteins have been identified within DBP: vitamin D -between residues 35 and 49; C5a -between residues 126 and 175; and actin -between residues 373 and 403. More detailed studies are needed to determine the Ab-binding domain in DBP and the DBP-binding region in Ab.
Soluble Ab is a natural metabolic product, and is present in the plasma and CSF of normal subjects and AD patients. 33 Because it is a crucial factor in the pathogenesis of AD, targeting Ab is therefore an effective therapeutic strategy, such as by Ab vaccination or anti-Ab immunotherapy. It has been suggested that only free or unbound Ab can participate in the formation of toxic aggregates. 8 Therefore, some Ab-binding molecules and proteins may play a role in the prevention of AD pathogenesis. CSF and plasma contain several circulating Ab-binding proteins, such as TTR, apoE, cystatin C, heat-shock proteins, and albumin, which have been suggested to be therapeutic in AD. [5] [6] [7] [8] 25 Endogenous Ab-binding proteins have been shown to (1) sequester Ab, resulting in an increase in the fraction of bound Ab and a decrease in the level of free Ab, (2) inhibit the aggregation and polymerization of Ab, thus preventing amyloid plaque formation, and (3) suppress Ab-induced cytotoxicity. [5] [6] [7] [8] DBP is an abundant protein in both plasma and CSF, 10, 11, 34 and our results show that, similar to other known circulating proteins that sequester Ab, secretory DBP binds to Ab and reduces Ab-mediated pathology. We have therefore discovered a novel endogenous Ab-binding protein with therapeutic potential.
The ThT assay and AFM analysis showed that DBP inhibits oligomerization of Ab, and may bind to a site or sites that are crucial for Ab polymerization and/or aggregation. Some residues in Ab peptides are crucial for Ab aggregation, fibrilization, and conformational change. 35, 36 Because of its Ab-binding function, DBP has a physiological significance in the pathogenesis of AD, but the contribution of the DBP-Ab interaction required elucidation. We first determined that DBP can bind to Ab and inhibit Ab oligomerization, and can influence Ab-mediated neuronal death in vitro. Using the cell viability and toxicity assays, we found that DBP has a protective effect on Ab-induced death of mouse hippocampal HT22 cell line ( Figure 5 ). One possible explanation for this effect is that DBP binds to monomeric Ab species, and blocks the formation of the highly toxic oligomeric species ( Figures  2a, 4, and 5a) . Second, DBP-AbO binding might mask regions that are required for its interaction with cellular targets and inhibit further aggregation or growth of AbO (Figures 2b,  4 , and 5b). Third, DBP might sequester AbO and subsequently reduce its binding to receptors and uptake (Figures 2b and 5b) .
In behavioral and histological studies, we demonstrated the protective effects of DBP on AbO-induced memory impairment and neurodegeneration in vivo (Figures 6 and 7) . Intracerebroventricular injection of AbO is known to result in memory deficits and synaptic loss in rodents, 37 and mice administered AbO in our study had cognitive impairment and a reduction in synaptic density in the hippocampus as shown by the Y-maze test and immunohistochemistry of synaptic markers, respectively. Interestingly, these cognitive and synaptic deficits were significantly improved by administration of DBP. The inhibiting effects of Ab-binding DBP on cognitive impairment is consistent with a previous study in which TTR, an Ab-binding protein, attenuated Ab-mediated deficits in 5 Because memory and synaptic deficits in AD are mainly caused by soluble AbO, the protective effects of DBP in a mouse model of AD constructed by intracerebroventricular injection of AbO can probably be attributed to the sequestration of AbO and subsequent blockage of its binding to the synapse, resulting in the inhibition of AbO-associated pathology. However, no significant neuronal loss was detected in the mice injected with AbO (data not shown).
The identification of changes in the level of circulating proteins in the plasma and CSF of AD patients supports the association between these proteins and the pathogenesis of AD. In AD patients, the concentration of circulating Ab-binding proteins, such TTR, b-trace, cystatin C, apoE, and albumin, is significantly altered compared with non-demented subjects. 32, 38, 39 Many studies have also shown alterations in the concentration of DBP in the CSF of AD patients, who demonstrated upregulation of DBP expression. 11, 15, 16 Based on these reports, Ab-binding proteins, including DBP, might provide effective diagnostic tools or biomarkers for AD. 32, 38, 39 It has been suggested that upregulation of neuroprotective and Ab-sequestering proteins, such as ADNP and cystatin C, in response to AD represents an intrinsic compensatory response that may counteract the progression of the disease. 40, 41 We propose that the imbalance in the expression level or failure (or deficit) in the Ab-chaperone activity of Ab-sequestering proteins, including DBP, may lead to the development of sporadic late-onset AD.
In addition to its Ab-binding effects, DBP may be relevant to numerous other pathological mediators of AD. There are several lines of evidence that an increase in extracellular actin in the CSF, vitamin D deficiency, neuroendothelial disruption, and immune dysfunction are commonly associated with AD pathology. [42] [43] [44] [45] Interestingly, DBP is known to act as an actin scavenger, a vitamin D transporter, a growth factor for endothelial cells, an immunmodulator, and a macrophage activator. 10, 46 Therefore, it is possible that DBP may improve the synaptic loss and inhibit memory deficits through the regulation of other pathological mediators of AD. There are no DBP-positive cells in the extrahypothalamic areas, including the cortex (Figure 3 ) and hippocampus (data not shown). Since DBP is a secreted protein, DBP produced in hypothalamic neurons (Supplementary Figure 1) might have functional effects in brain areas with more direct relevance to AD.
Although we showed that DBP has preventive effects on AbO-mediated pathology in vivo and DBP directly binds to Ab and inhibits aggregation in vitro, there is no direct evidence to elucidate whether DBP affects Ab aggregation in vivo. Further work, such as generation of new DBP transgenic mouse models, will be needed to determine if DBP actually influences Ab metabolism or Ab aggregation in vivo.
In conclusion, we have demonstrated for the first time that the direct binding of DBP to Ab suppresses Ab-related pathology in vitro and in vivo. Our results suggest that increasing the levels of DBP may be a promising therapeutic strategy for AD.
Materials and Methods
Pull-down assay. Various concentrations (1, 5, and 25 mg) of biotin-Ab (American Peptide, Sunnyvale, CA, USA) and DBP from human plasma (Sigma, St. Louis, MO, USA) were mixed in binding buffer (50 mM Tris, pH 7.5, 300 mM NaCl, 0.05% NP-40) and incubated at 4 1C for 12 h to allow the formation of Ab-DBP complexes. The samples were then incubated with streptavidin-Sepharose beads (GE Healthcare, Piscataway, NJ, USA) in a rotating shaker at 4 1C for 2 h. Subsequently, proteins were boiled in 2 Â SDS sample buffer at 100 1C and were loaded onto 15% Tris-glycine gel, followed by analysis with western blot. DBP (58 kDa) bound to Ab was immunodetected using a rabbit anti-human DBP polyclonal antibody (1 : 1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). We also found immunopositive Ab bands using an anti-Ab monoclonal antibody 6E10 (Covance, Emeryville, CA, USA).
SPR spectroscopy. The SPR protocol for the study of real-time direct binding of Ab and DBP was essentially similar to that described previously 47, 48 and was performed using a Biacore X-100 (GE Healthcare). The CM5 sensor chip (GE Healthcare) was preactivated by a mixture of N-hydroxysuccinimide and N-ethyl-N'-(dimethylaminopropyl) carbodiimide. DBPs (20 mg/ml; Sigma) were immobilized separately by N-ethyl-N'-(dimethylaminopropyl) carbodiimide -Nhydroxysuccinimide amine coupling on the CM5 sensor chip. As a control, the same volume of HBS-EP buffer was applied to the chip surface and the unreached sites were blocked by injection of ethanolamine. To analyze the binding kinetics, different concentrations of Ab diluted in HBS-EP buffer were injected onto the sensor chip for 540 s at 10 ml/min, and the response unit (RU) was then recorded at 25 1C. After injection of the analyte was stopped, HBS-EP buffer was poured over the chip for 700 s at 10 ml/min to allow the bound analytes to dissociate from the immobilized DBP, and dissociation curves were obtained. The RU elicited by injecting HBS-EP buffer alone was used as the control. Biacore X-100 software (GE Healthcare) was used to record the changes in RU and to plot the binding curve. The curves obtained from the SPR experiments were analyzed and the dissociation equilibrium constant (K D ) of Ab to immobilized DBP was calculated using kinetic evaluation software. The dissociation constant K D (M) was derived from the equation, K D ¼ k d /k a , where k d and k a are dissociation and association rate constants, respectively.
Preparation of monomeric and oligomeric Ab 1-42 solutions and aggregation assay using AFM and ThT assay. To obtain a solution of Ab 1-42 monomers, lyophilized Ab 1-42 (American Peptide) was dissolved in 1,1,1,3,3,3-hexafluoroisopropanol (Sigma-Aldrich, St. Louis, MO, USA), evaporated, re-dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich), and then diluted in PBS (pH 7.4) to yield a final concentration of 1 mM. Solutions of oligomeric Ab 1-42 were prepared as described previously. 49 To prepare the oligomer solution, monomeric Ab 1-42 peptides were incubated with PBS at 4 1C for 24 h and immediately stored in aliquots at À 80 1C. To examine the effect of DBP on oligomeric Ab 1-42 formation, peptide solutions containing Ab 1-42 monomers (10 mM) with and without DBP (100 mg/ml) were incubated at 4 1C for 24 h. DBPfree samples were treated with the same volume of distilled water. The resulting oligomers were examined by AFM (PARK Systems Inc., Suwon, South Korea) as described previously. 48 To estimate oligomer size using AFM, peptide solutions were aliquoted from reaction mixtures and immediately spotted onto freshly cleaved micas. The micas were then rinsed with water two times, and dried in air. AFM images were examined to quantify the size of oligomeric Ab 1-42 , the average perimeter of detectable white particles in each image, using Image J program (National Institutes of Health). The effect of DBP on aggregation of monomeric Ab 1-42 was examined using ThT assay as described previously. 50 The solutions of monomeric Ab 1-42 (5 ml of 100 mM in DMSO) and 5 ml of DBP (1, 10, and 100 mg/ml in PBS) or PBS were added to 40 ml PBS at pH 7.4. The resulting mixture was incubated for 2 h at room temperature (RT). To the resulting mixture, 150 ml of ThT solution (5 mM in 50 mM glycine-NaOH at pH 8.5) was added. The ThT fluorescence was measured at 490 nm with excitation at 450 nm in a Tecan Infinite M200 Fluorescence Microplate Reader (Männendorf, Switzerland).
Cell cultures and cell death assay. To study the effect of DBP on Ab toxicity, we used mouse hippocampal HT22 cells (donated by Dr. David Schubert at Salk Institute, La Jolla, CA, USA) exposed to Ab as an in vitro model of AD. The cells were incubated with 1 or 5 mM Ab 1-42 for 24 h in the presence or absence of DBP (1, 10, and 100 mg/ml). DBP peptides were pretreated 30 min before the addition of Ab . The degree of cell viability or cell survival was measured using the MTT assay, MTS assay, and DAPI staining as described previously. [51] [52] [53] The relative reduction of MTT and MTS was quantified by measuring optical density at 560 nm using a plate reader (Bio-Tek Instruments, Winooski, VT, USA). DAPIstained cells are counted using Image-Pro Plus Version 6.0 (Media Cybernetics, Bethesda, MD, USA). The MTT assay, MTS assay, and DAPI staining were performed in triplicate and independently repeated two times. Data are presented as a percentage of control, vehicle-treated cells.
Stereotaxic injection of AbO and DBP into mouse brains. Male C57BL/6 mice (22-25 g, 8 weeks of age) were used for all of the experiments. They were given access to water and food ad libitum and were housed in a controlled environment at a constant temperature (23±1 1C) with a 12 h light/dark cycle. All animal procedures were carried out in accordance with the Principle of Laboratory Animal Care (NIH Publication No. 85-23, revised 1985) and the Animal Care and Use Guidelines of Kyung Hee University (Seoul, Korea). The AbOinjected animal model of AD was constructed according to a previous method. 22 All stereotaxic surgical procedures were performed on anesthetized mice (mixture of Zoletil 50 (Virbac, Carros, France) and Rompun (Bayer Korea, Seoul, Korea), 3 : 1 ratio, 1 ml/kg intraperitoneally) that were mounted in a stereotaxic apparatus (myNeuroLab, St. Louis, MO, USA). Soluble AbO (10 mM in 3 ml) was injected into the lateral ventricle ( À 0.6 mm anterior-posterior (AP), 1.2 mm medial-lateral (ML), and À 2 mm dorsal-ventral (DV)), relative to the bregma using a Mouse Brain Atlas, 54 at a rate of 0.5 ml/min. Sham-operated groups were administered with the same volume of saline. To study the effects of DBP in AbO-injected mice, 3 ml DBP (20 mg) were also injected into the lateral ventricle ( À 0.4 mm AP, 1.2 mm ML, and À 2 mm DV) 20 min before administration of AbO. Control animals were injected in parallel with saline.
Behavioral memory impairment test. Spontaneous alternation Y-maze was performed as described previously.
22,55 Short-term spatial recognition memory was investigated using the Y maze 6 days after stereotaxic surgery. The Y maze is composed of three arms with equal angles between the arms. The floor and walls of the maze were made of dark opaque polyvinyl plastic. Mice were placed in one arm, and were allowed to explore the maze freely. The alternation and the total number of arm entries (locomotor activity) were counted manually for each mouse during an 8-min session. Alternation was defined as consecutive entries into all three arms without repetition. The percentage of alternations was calculated as follows: ((the number of alternations)/(the total number of arms entered-2)) Â 100.
Immunohistochemistry and quantification of immunoreactivity.
For histological examination of the brain, mice were killed 8 days after stereotaxic surgery. Animals were anesthetized with a mixture of Zoletil and Rompun solution (3 : 1 ratio, 1 ml/kg intraperitoneally) and were then transcardially perfused with a cold solution of 4% paraformaldehyde in PBS. The brains were dissected and postfixed for 20 h in the same fixative solution before being immersed in a cryoprotectant solution of 30% sucrose in PBS. The brain tissues were cut into 30-mm-thick coronal sections with a cryostat (Leica, Nussloch, Germany) at À 25 1C and stored at 4 1C. Four brain sections from each mouse were taken from the region between À 1.3 and À 2 mm relative to the bregma. 54 The freefloating brain sections were then pretreated with 1% hydrogen peroxide for 15 min to inhibit endogenous peroxidase. Tissue sections were then incubated at 4 1C overnight with mouse anti-synaptophysin antibody (1 : 200; Sigma-Aldrich) or rabbit anti-PSD-95 antibody (1 : 1000; Abcam, Cambridge, MA, USA). Subsequently, the sections were incubated with biotinylated horse anti-mouse IgG antibody or biotinylated goat anti-rabbit IgG antibody (1 : 200; Vector Laboratories, Burlingame, CA, USA) and avidin-biotin-peroxidase complex solution and then visualized with 3,3 0 -diaminobenzidine as the chromogen. To quantify immunoreactivity, the images were processed and analyzed using ImageJ program. The analysis was performed blindly in both hemispheres of four brain sections per animal. To measure the optical density of synaptophysin and PSD-95 immunoreactivity, the region of interest -the stratum radiatum of CA1 and the stratum lucidum of CA3 -was manually outlined and the average optical densities were acquired in the captured 8-bit grayscale images.
Double immunolabeling for DBP and Ab in the brain of AD patients and 5XFAD mice. Human brain samples were obtained from Boston University Alzheimer's Disease Center and followed guidelines by Boston University School of Medicine. The detail information of brain tissues is described in Supplementary Table 1. Transgenic mice with 5XFAD used in this study were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). These mice
